K2 Principal Fund, L.P. Cyma Bay Therapeutics, Inc. Transaction History

K2 Principal Fund, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$4.23 - $6.55 $303,976 - $470,696	-71,862 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$5.73 - $9.03 $411,769 - $648,913	71,862 New	71,862 $412,000
Q2 2020 Aug 13, 2020	SELL	$1.41 - $4.25 $117,169 - $353,170	-83,099 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.25 - $2.02 $103,873 - $167,859	83,099 New	83,099 $123,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of K2 Principal Fund, L.P., based on Form 13F filings with the SEC.

Stay updated on K2 Principal Fund, L.P. with notifications on news.